Wisdom Finance APP News, Fosun Pharma (02196) has announced that its controlling subsidiary, Shanghai Henlius Biotech Co., Ltd., and its controlling subsidiaries (hereinafter referred to as "Henlius") recently received approval from the National Medical Products Administration for conducting clinical trials of HLX22 (i.e. a humanized monoclonal antibody injection targeting human epidermal growth factor receptor-2 (HER2)) in combination with pertuzumab and chemotherapy or trastuzumab emtansine for treating solid tumors expressing HER2 (referred to as "such treatment regimen"). Henlius plans to conduct Phase II clinical trials of this new drug in China (excluding the Hong Kong, Macao and Taiwan regions, the same below) when conditions are met.